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Abstract
Background: Coronary artery disease (CAD) is the most common heart disease worldwide. Association of CAD with variants
in the myocyte enhancer factor 2A (MEF2A) gene, the first identified CAD-causing gene, has attracted special attention but
the results are controversial. We aimed to evaluate this genetic association via a case-control study and meta-analysis.
Methodology/Principal Findings: We performed a case-control association study to investigate the relationship between
variations in exon 11 of MEF2A gene and CAD in 1045 sporadic patients and 1008 controls enrolled angiographically among
southern Chinese population, and then the data from this study were compared and discussed in a systematic review and
meta-analysis with all available published studies on MEF2A gene and CAD. In total, eight variants were identified (21-bp
deletion, CAG repeats, CCG repeats, a CCA deletion and four SNPs). No significant link was observed between the common
(CAG)n polymorphism and CAD, whereas the rare 21-bp deletion was detected only in five affected individuals. The meta-
analysis of (CAG)n polymorphism and CAD risk, including nine studies with 3801 CAD patients and 4020 controls, also
provided no convincing evidence for the genetic association, even upon stratification by race (mainly Whites and Chinese).
However, the 21-bp deletion was regarded as a potentially logical, albeit undetermined, candidate for CAD in the following
systematic review.
Conclusions/Significance: Our findings failed to demonstrate a correlation between (CAG)n polymorphism with CAD,
however, we concluded that the rare 21-bp deletion might have a more compelling effect on CAD than the common (CAG)n
polymorphism, and MEF2A genetic variant might be a rare but specific cause of CAD/MI.
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Introduction
Coronary artery disease (CAD) is a common complex disorder
resulting from both genetic and environmental influences [1,2],
and it has become a major cause of death and disability in China.
The role of genetic alterations and their impact on CAD
susceptibility remains unclear and has attracted more attention.
In the past three decades, genetic association studies and genome-
wide linkage scans have revealed a considerable number of
candidate loci and genes for CAD and myocardial infarction (MI)
[3–7], but results are not often reproducible [8–10].
In 2003, a 7-amino acid deletion, caused by a 21-base pair (bp)
coding sequence deletion in exon 11 of the myocyte enhancer
factor 2A (MEF2A) gene, was reported as a causative mutation in a
single large CAD/MI family of Scandinavia ancestry [11]. In vitro
functional analysis indicated that the 21-bp deletion disrupted the
nuclear localization of mature protein and decreased MEF2A-
induced transcriptional activation. Thus this genetic imperfection
might lead to a defective or abnormal vascular endothelium, which
could promote the genesis of atherosclerotic plaque or thrombosis
and influence the whole process of atherogenesis [11]. Subsequent-
ly, the same researchers discovered three functional variants
(Asn263Ser, Pro279Leu and Gly283Asp) in exon 7 in approxi-
mately 2% of the affected population, but none in unaffected
individuals [12]. Thence, MEF2A gene has been considered as the
first CAD-causing gene to be identified.
The genomic sequence of MEF2A gene is highly polymorphic. It
is thus of added interest to detect which or how many MEF2A
genetic variants might have functional potential to affect the final
bioavailability of MEF2A, and further the development of CAD. In
fact, many case-control studies have attempted to investigate the
unequivocal effects of MEF2A gene on CAD, especially its exon
11, claimed as the most polymorphic locus harboring various
substitution and insertion/deletion (indel) polymorphisms such as
a common variant (CAG)n polymorphism. However, the results
have been inconsistent [13–20].
With the improved genotyping technologies and the completion
of the human HapMap project, Genome-Wide Association
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in genetic research. Thus far, a large number of candidate loci
conferring risk of or protection from common complex diseases
such as CAD have been proposed [21–25]. Nonetheless, neither
the MEF2A locus on chromosome 15q26 nor its adjacent region
has been identified in any of the previous GWASs, thus gene-
rating debate over the nature of MEF2A genetic contribution to
individual susceptibility to CAD.
To elucidate the relationship between MEF2A gene and its
effect on CAD risk, we focused on its exon 11, the highly
polymorphic and controversial region, and established a well-
characterized case-control study of 1045 sporadic CAD patients
and 1008 controls with normal coronary arteries. In addition, we
reviewed all available studies reported in the literature to examine
the association of the common (CAG)n polymorphism and the rare
21-bp deletion with CAD, and to assess whether variations in
study design and study population ethnicity could lead to potential
biases and be the sources of between-study heterogeneity.
Materials and Methods
Case-control study
Ethics Statement. Approval to undertake this study was
granted by the Ethics Review Committee of Ruijin Hospital,
Shanghai Jiao Tong University School of Medicine and was
conducted according to the Declaration of Helsinki Principles.
Written informed consents were obtained from each participant at
enrollment.
Study population. This was a hospital-based case-control
study including a total of 2053 unrelated Han Chinese admitted to
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
when they were experiencing various symptoms or for a medical
checkup from January 2006 to September 2009. All participants
underwent coronary angiography and were divided into CAD
group and control group according to their angiographic results.
The CAD group contained 1045 sporadic patients aged
65.4969.83 years, and the diagnosis of CAD was determined
angiographically based on the presence of more than 70% stenosis
in at least one of the three major coronary arteries or major
branches. Patients with simple spasm of coronary arteries,
myocardial bridge or other non-coronary atherosclerotic lesions
were excluded. The remaining participants (n=1008), aged
60.23610.49 years, had normal coronary arteries (NCA) on
angiography, formed the control group.
All patients with the 21-bp deletion were followed up every year
in a special CAD clinic. At each visit, clinical manifestations and
echocardiography were recorded. Adverse events (e.g. hospital-
ization, cardiac dysfunction, percutaneous coronary intervention,
coronary artery bypass grafting, or death) were reported during
the visit or through telephone conversation with the patients or
their family members. Two trained physicians independently
reviewed all medical notes, including emergency department visit
forms and hospital medical records.
Screening for variations in MEF2A exon 11. Blood
samples (5 ml) were drawn and genomic DNA was extracted
from peripheral blood leukocytes by standard phenol-chloroform
extraction. To assess the distribution patterns of the structural
variations of MEF2A exon 11 in this cohort study, we sequenced
the entire exon 11 using the direct DNA sequencing method in all
2053 subjects. Primers were designed by the Primer3 software
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3) according to
reference sequence (NM_005920.2). In detail, the sequence of the
forward primer was 59-gca gag gta ctt gca agc cat ctg-39 and the
reverse was 59-ggt cgg cca agc aca att gga gaa-39. The sequencing
primer was 59-caa gca caa ttg gag aat gga-39. Sequences were
analyzed using an ABI Prism BigDye Terminator Cycle
Sequencing Kit on an ABI Prism 3700 sequencer, version 3.1
(Applied Biosystems, Foster City, CA, USA), as described in detail
in Text S1.
Systematic review and meta-analysis
Data sources and search strategies. We collected information
via two international searching engines, viz. PubMed and
Excerpta Medica Database (EMBASE), and two Chinese
searching engines, viz. Wanfang database (http://www.
wanfangdata.com.cn) and China Biological Medicine (CBM)
(http://sinomed.imicams.ac.cn/index.jsp) with the last update
on July 31, 2011. We restricted search results to papers published
in English or Chinese. We combined the subject terms of
‘coronary artery disease or coronary disease or arteriosclerosis or
atherosclerosis or myocardial infarction or angina pectoris’ and
‘myocyte enhancer factor 2A’ with either ‘gene’, ‘variation’,
‘variant’, ‘mutation’, ‘polymorphism’ or ‘allele’, which were all
MeSH (Medical Subject Headings in the US National Library of
Medicine) terms. The ‘‘related articles’’ in the MEDLINE option
as well as reference lists of all retrieved studies were also checked
for citations of other relevant publications that were not identified
initially. All studies were considered potentially eligible if they
aimed to investigate the relationship between MEF2A genetic
polymorphisms and CAD risk. If there were multiple publications
from the same study group, the most complete and recent results
were extracted. Search results were limited to studies performed
in human subjects without country restrictions and ethnic
restrictions.
Inclusion/exclusion criteria. We enrolled all prevalent
case-control or nested case-control or cross-sectional studies in
this meta-analysis regardless of sample size, if 1) they explored the
association of MEF2A genetic polymorphisms with CAD/MI, 2)
genotyping had been performed by using validated methods, and
3) they provided the sufficient information on genotype/allele
counts or frequencies for estimating odds ratio (OR) and 95%
confidence interval (95% CI). We calculated the effect estimate
against healthy subjects/NCA controls.
Data extraction. Data were extracted independently and
entered into separate databases by two authors (Y. Liu and W.
Niu) from each qualified study: first author’s last name, publication
date, population ethnicity, study design, diagnostic criteria,
genotyping methods, baseline characteristics of the study
population, such as age, gender, history of hypertension and
diabetes mellitus, if available, and the number of persons with
different alleles in cases and controls and available subgroups.
Discrepancies between the two databases were identified by
comparison. A third author (W. Jin) checked for them and a
consensus was reached after discussion. For consistency,
continuous variables such as age were uniformly expressed as
mean 6 standard deviation (S.D.)
Statistical analysis. For our case-control study, database
management and statistical calculation were conducted using SPSS
version 13.0 (SPSS Inc., Chicago, Illinois, USA). The Student’s t-
testforcontinuousvariablesandthex
2-testforcategoricaloneswere
used to test differences between cases and controls, OR of CAD risk
and their 95% CI were calculated as well.
Hardy-Weinberg equilibrium calculations were performed
with the Arlequin program (http://anthro.unige.ch/software/
arlequin). The Haplo.stats package (version 1.4.0) in the R
statistical computing software (http://www.r-project.org) was used
to analyze haplotype-based association study. Two-tailed P,0.05
was accepted as statistically significant.
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(CAG)n polymorphism to CAD risk was performed by the
Review Manager software (version 5.0.19; http://www.cc-ims.
net/revman/download). Using the most common type (CAG)9
allele as a reference, comparisons of other (CAG)n alleles between
cases and controls were expressed in the form of OR and 95% CI.
The allele effects were estimated using the model-free approach,
where no assumption about genetic models was required. In
addition, stratification analyses were conducted to seek more
narrowly drawn subsets of the studies such as different genotyping
methods, population origins and study designs. We implemented
the random-effects model using the method of DerSimonian and
Laird, instead of fixed-effects model, to bring the individual effect-
size estimates together, and the estimate of heterogeneity was
analyzed by the Mantel-Haenszel method [26–28].
The presence of between-study heterogeneity across all eligible
comparisons was calculated using the x
2-based Cochrane’s Q
statistic with statistical significance at the level of 0.10 as this
statistic has proven to have poor power if there are few studies
[28,29]. Besides, the I
2 statistic was documented for the percentage
of the observed between-study variability due to heterogeneity
rather than chance with the ranges of 0–100% (I
2=0–25%, no
heterogeneity; I
2=25–50%, moderate heterogeneity; I
2=50–
75%, large heterogeneity; I
2=75–100%, extreme heterogeneity)
[28].
Finally, publication bias was assessed by the fail-safe number
(Nfs) of each meta-analysis [30]. If the Nfs was smaller than the
number of observed studies for a polymorphism, it is believed that
the meta-result might have a significant publication bias. In this
study, the Nfs significance was established at P,0.05 (Nfs0.05=(SZ/
1.64)
22k; where k is the number of articles included in each meta-
analysis).
Results
Clinical characteristics of our study population
The clinical characteristics of our study population are shown
in Table S1. Compared with NCA controls, CAD patients were
older (P,0.001) and more often of the male gender (P,0.001).
As expected, the CAD group had a higher prevalence of
conventional cardiovascular risk factors, including diabetes and
dyslipidemia (P,0.05). They had higher serum levels of fasting
glucose, total cholesterol, triglycerides, and low density lipopro-
tein-cholesterol, and lower levels of high density lipoprotein-
cholesterol. However, the morbidity of hypertension was similar
between the two groups.
Genetic information on our case-control study
Eight variants were identified by sequencing the entire exon 11
in 2053 unrelated Chinese individuals (Table 1). No significant
deviation from the Hardy-Weinberg equilibrium was detected for
each polymorphism in both CAD patients and NCA controls.
The number of the CAG triplet repeats (polyglutamine tandem
repeats, (Q)n) spanned from 4 to15, and the majority of individuals
had 9–11 repeats. Shown in Table 2 are the allele distributions of
(CAG)n polymorphism. No statistical significance was observed
(P=0.347) for the allelic association of this polymorphism with
CAD, and the distribution of genotypes was also similar in two
groups (data not shown).
Closely following the (CAG)n polymorphism was the CCG
triplet repeats varying between 4 and 5 proline tandem repeats (P4
or P5). More than 95% of individuals in both CAD patients and
NCA controls contained five prolines, and the frequencies of
(CCG)n allele and genotypes yielded no significant differences
between two groups (data not shown). Additionally, a CCA
deletion resulting in lack of one proline amino acid, located
adjacent to (CCG)n site, was detected only in one unaffected
subject.
Interestingly, the 21-bp deletion was found only in five
independent CAD patients, and none in NCA subjects. In this
cohort, they all had some traditional CAD risk factors, including
dyslipidemia, hypertension and family history of cardiovascular
diseases; three showed severe lesion in the left main coronary
artery and two were diagnosed with premature CAD. After a 5-
year follow up, one died of sudden cardiac death, one took stent
treatment and three underwent coronary artery bypass grafting
(Table S2).
Table 1. Genetic variations in MEF2A gene exon 11 discovered by sequencing in our study population.
Categories Variants AA code
1 MAF (allele frequency, %) P value; OR [95% CI]
CAD Cases(n=1045) Controls(n=1008)
STR (CAG)n (1257–1290) (Q)n (n=4–15) More details in Table 4.
Deletion CCG (1291–1293) P deletion
(n=4 or 5, 431/432)
111(5.3) 109 (5.4) 0.892; 1.019 [0.777,
1.337]
CCA (1297–1299) P deletion (433/434) 0 1(0.05)
21-bp deletion
(1303–1337)
QPPQPQP deletion
(434–446 AA)
5(0.2) 0
SNP A1299G P433P 1(0.05) 1(0.05) 0.980; 1.036 [0.065,
16.571]
C1303T P435S 9 (0.4) 5 (0.2) 0.315; 0.574 [0.192,
1.717]
G1305A P435P 92 (4.4) 91 (4.5) 0.867; 0.975 [0.725,
1.312]
G1353T G443G 693 (33.2) 689 (34.2) 0.490; 1.047 [0.920,
1.191]
1Q=Gln; P=Pro; S=Ser; G=Gly.
STR: short tandem repeat polymorphism; SNP: single nucleotide polymorphism; AA: amino acid; MAF: minor allele frequency; OR: odds ratio; 95%CI: 95% confidence
interval.
doi:10.1371/journal.pone.0031406.t001
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e31406Besides the aforementioned four variants, we identified three
synonymous SNPs (A1299G, G1305A, and G1353T) and one
non-synonymous SNP (C1303T) in exon 11. The A1299G and
C1303T polymorphisms were rare SNPs with minor allele
frequencies being 0.1% and 0.4% among NCA controls,
respectively. As a result, none of these four SNPs were associated
with CAD (data not shown).
After dropping four rare variations (21-bp deletion, CCA
deletion, A1299G and C1303T polymorphisms), we evaluated the
remaining four common variants for further haplotype analysis.
Using the most common haplotype (Q)9-P5-G-T (in order of
(CAG)n, (CCG)n, G1305A and G1353T) (26.0% in NCA controls)
as the baseline for the comparison of the rest, the differences in
haplotype distributions between the two groups did not achieve
nominal significance (data not shown).
Meta-analysis results of (CAG)n polymorphism
The initial search strategy retrieved forty-three relevant articles
in English (n=24) and Chinese (n=19), in which the effect of
MEF2A gene variations on CAD was evaluated. A total of fifteen
studies met selection criteria, whereas only eight studies [13,14,17–
19,31–33] were tailored to the inclusion criteria in the meta-
analysis because six [15,16,20,34–36] lacked the necessary
information on (CAG)n genotypes/alleles, and one shared the
same population [19,37]. Twenty-five studies, including fourteen
review papers, comments and editorials, and fourteen relating to
other diseases or polymorphisms in MEF2A gene, were exclu-
ded for the final analysis. The flow chart of study selection was
summarized in Figure 1. Therefore, data from nine studies,
including the present study, totaling 3801 CAD patients and 4020
controls were finally identified in the meta-analysis. Of these, five
studies were carried out on Chinese (including this study, 61.85%)
[14,18,19,31], three on Whites (36.16%) [13,17,33] and one on
Turks (1.99%) [32].
The demographics and clinical features of all eligible studies are
summarized in Table 2. The sample sizes ranged from 156 to
2061. The percentage of males ranged from 72.4% to 87.4% in
CAD patients and 49.4% to 79.8% in controls. The mean age was
greater than 56 years old in CAD patients and 51 in controls. All
studies had allele data of (CAG)n polymorphism except for two
with only genotype counts [14,32]. Seven studies provided
information on this polymorphism associated with CAD/MI,
and two with MI only [32,33]. The (CAG)9 allele frequency
differed widely in diverse ethnic groups. In Whites, the frequencies
were in the ranges of 32.2% to 36.2% for CAD cases and 30.6% to
36.3% for controls, which were lower than that in Chinese ranging
from 24.3% to 40.5% for cases and 22.7% to 41.8% for controls.
In contrast, the Turks had a higher frequency of 51% for cases and
33.5% for controls (Table 2).
As shown in Figure 2, compared with other tandem repeats
carriers, those with the (CAG)9 allele yielded a non-significant 15%
increased risk for CAD (95% CI=0.97–1.37, P=0.1) under a
random-effects model. Whereas, of nine studies, only two individual
OR estimates showed a higher risk of CAD that was statistically
significant for (CAG)9 allele compared with other alleles (Han et al.:
OR=1.96,95%CI=1.55–2.47,P,0.001;Gulecetal.:OR=2.06,
95% CI: 1.30–3.26, P=0.002, respectively).
However, statistically significant heterogeneity was evident in
most subgroups, according to covariates identified by our
qualitative assessment (Table 3). In view of genotyping methods,
we classified the nine studies into sequence (including this study)
[13,17,19]/other (matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry, MALDI-TOF MS) [18] and PCR-
SSCP (single-strand conformational polymorphism analysis)
[14,31–33] groups. There was no significant heterogeneity in the
sequence/other group (OR=1.00, 95% CI: 0.90–1.11; Pheterogeneity
=0.25). In comparison, studies in PCR-SSCP group were
heterogeneous (OR=1.41, 95% CI: 0.94–2.12; Pheterogeneity
Figure 1. Flow chart of studies identified through the systematic literature search.
doi:10.1371/journal.pone.0031406.g001
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did not affect the overall results materially.
After stratification by control selection criteria based on clinical
symptoms or coronary angiographic data, significant heterogene-
ity was observed in both the NCA group and the symptom
investigation group (Pheterogeneity=0.01 and ,0.00001, respectively).
Moreover, negative associations persisted across all comparisons.
We divided the population into three groups by ethnicity,
Chinese (including this study) [14,18,19,31], White (Spanish,
German and Canadian) [13,17,33] and Turk [32]. Although, there
was no evidence of heterogeneity in White population (OR=0.99,
95% CI: 0.88–1.11; Pheterogeneity=0.62), it was significant in Chinese
population possibly due to the wide spectrum of (CAG)9 allele
(OR=1.18, 95% CI: 0.90–1.54; Pheterogeneity,0.00001). Since there
was only one study performed in Turks with a relatively small
sample size (n=156), the risk estimate showed a significant higher
risk of (CAG)9 allele with CAD (P=0.002), and there was no
difference in the pooled risk estimates.
To assess publication bias, we calculated the fail safe number
(Nfs) at the level of 0.05 for each comparison. The Nfs0.05 values for
all the comparisons were greater (62.63) than the number of
studies (n=9) included in this meta-analysis. Therefore, no
evidence showed publication bias for association between MEF2A
gene (CAG)n polymorphism and CAD susceptibility.
Systematic review of the 21-bp deletion
Of the forty-three potentially relevant studies and the present
study, fourteen were eligible for a systematic review of the 21-bp
deletion and CAD risk, and thirty studies were excluded (Figure 1).
Three of these were family-based studies and the remaining eleven
used a hospital-based case-control design (Table 4). Of the latter,
four studies (including this study) [14,19,38] had used coronary
angiography as critical criteria for classification the enrollments,
and four studies (including this study) involved more than 1000
subjects in controls [13,17,20]. Seven studies were conducted on
Whites (53.85%) [11,13,17,20,33,34,38], six on East Asian
populations (including this study, 38.46%) [14,16,18,19,39] and
one on Turks (7.69%) [32]. The frequency of the 21-bp deletion in
sporadic patients differed substantially, from 0.09% to 1.92%,
mainly 0.16% in Whites [20,38] and 0.65% in Asian (including
this study) [16,19,39], all were less than 5%. Two studies on
Whites [17,20] and one on Japanese [16] confirmed the 21-bp
deletion in controls (not angiographically tested), and the
frequency was 0.12% and 0.51%, respectively. The overall
Table 3. Meta-analysis of the effect of (CAG)9 allele on CAD risk according to potential sources of heterogeneity.
Studies (cases/controls), N (n/n) (CAG)9 repeats carriers
Overall effect (Z, OR [95%CI], P value) Heterogeneity (I
2, P value)
Genotyping methods
Sequence/other 5 (2636/2167) 0.07, 1.00 [0.90, 1.11], 0.94 26%, 0.25
PCR-SSCP 4 (1165/1853) 1.66, 1.41 [0.94, 2.12], 0.10 90%, ,0.00001
Control selection
Symptom investigation 5 (1368/2132) 1.24, 1.13 [0.93, 1.38], 0.21 68%, 0.01
Normal angiography 4 (2433/1888) 0.90, 1.16 [0.84, 1.61], 0.37 90%, ,0.00001
Ethnic
White 3 (1041/1787) 0.22, 0.99 [0.88, 1.11], 0.82 0%, 0.62
Chinese 5 (2691/2146) 1.22, 1.18 [0.90, 1.54], 0.22 88%, ,0.00001
Turk 1 (69/87) 3.08, 2.06 [1.30, 3.26], 0.002 N/A
CAD: coronary artery disease; PCR: polymerase chain reaction; SSCP: single strand conformational polymorphism analysis.
doi:10.1371/journal.pone.0031406.t003
Figure 2. The comparison of the MEF2A (CAG)9 allele versus other alleles (with 4–8, 10–15 repeats) under a random effects model.
doi:10.1371/journal.pone.0031406.g002
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combined populations of studies published to date.
As shown in Table 4, more than half of patients bearing the
deletion either suffered severe CAD who had undergone
percutaneous coronary intervention or coronary artery bypass
grafting, or had some traditional CAD risk factors, such as
hypertension, diabetes, dyslipidemia, smoking, drinking, and/or
family history of CAD/MI or sudden death. But, the results of
different studies were inconsistent. Hsu et al. [18,33] failed to
detect this rare variant in CAD patients. In contrast, Weng et al.
[17] discovered this deletion in unaffected individuals rather than
in CAD patients. However, Kajimoto et al. [16,20] reported this
variant in both CAD patients and controls, and Gonza ´lez et al.
[13,14,32,34] did not reveal this deletion in any subject of the
study population.
Discussion
In the present study, we verified eight variants in MEF2A exon
11 and found that the most conspicuously heterogeneous variant
was the (CAG)n polymorphism, while the other seven were all
downstream of this polymorphism within 100 bp. Such intense
variation in the context of a single exon led us to explore the link of
MEF2A genetic polymorphisms to CAD/MI. A possible explana-
tion might be the remarkable diversity embedded in (CAG)n
polymorphism. We therefore carried out a rigorously-designed
case-control association study focusing on MEF2A exon 11 in
southern Chinese and reviewed all available information regarding
the relationship between this genetic hotspot and sporadic CAD/
MI from the literature. To the best of our knowledge, this is the
first meta-analysis seeking to clarify the association of MEF2A gene
(CAG)n polymorphism with CAD risk.
Data from our case-control study, which was in concordance
with most previous observations, and in combination with all other
eight studies involving a total of 3801 CAD patients and 4020
controls, failed to show a significant association between (CAG)n
polymorphism and CAD susceptibility, even upon stratification by
race (mainly Whites and Chinese). This meta-analysis had
sufficient statistical power [40] to detect such genetic effect.
Therefore, it is reasonable to surmise that either (CAG)n
polymorphism itself exhibits null association with CAD, or its
effect on CAD is small and depends on neighboring variants that
compensate or dilute the variation under study.
Noteworthy, one study conducted by Han et al. [14] in a small
northern Chinese cohort showed a positive and independent
association of (CAG)9 allele with an increased risk and severity of
CAD, while data from Dai et al. [19] in another 1139 northern
Chinese cohort displayed a marginal significance (P=0.052).
However, in our present study, we failed to replicate this association
in southern Chinese, which was in line with two other Chinese
populations [18,31] and in agreement with the pooled estimate of
this meta-analysis. Except for the differences in diet and climate
between northern and southern China, this discrepancy might be
caused by misgenotyping as discussed by Hsu et al. [18]. All
participants in Han’s study were homozygous for (CAG)n polymor-
phism; the phenomenon was not compatible with the situation
expected from random mating. After separating analyses by
genotyping methods, we found that heterogeneity between studies
in the PCR-SSCP group was higher than the overall estimate;
however, there was no indication attributable to the diversity
between different experimental methods. Nevertheless, applying
appropriate genotype techniques remain an open question.
Moreover, it is well known that CAD is frequently asymptom-
atic and the diagnosis relies on coronary angiography. However,
the definition of controls was debatable in a number of the
available studies. Some controls were enrolled according to their
clinical symptoms and should have been properly defined as
‘‘uncertain phenotype’’ [41], whereas some were on the basis of
explicit coronary angiographic results. Thus we cannot exclude
the possibility that the apparently healthy elderly controls had
underlying CAD, and so confuse and bias the study conclusions.
Therefore, our meta-analysis pinpointed the different selective
criteria of controls as a potentially significant source of between-
study heterogeneity. Nevertheless, deviation in the controls did not
appear to be a significant source of between-study heterogeneity.
Although this observation seems counterintuitive in terms of
selective criteria, considering the relative small sample sizes even
in the present meta-analysis and the possibility that (CAG)n
polymorphism might not be a major contributing locus or have
limited values to assess an exact role of MEF2A in CAD/MI, we
maintain that application of coronary angiographic criteria for
controls is preferable, and the proper phenotype discrimination is
critical in any genetic association study.
Meanwhile, we observed the wide divergence of (CAG)n repeats
across different populations. Specifically, the high versus low
frequency of (CAG)9 allele was nearly double in both CAD
patients and controls, suggesting a possible role of differences in
genetic background and the environment in which the populations
live. Of note, there was only one eligible Turkish population [32],
and there was statistical evidence of heterogeneity between
subgroups only in this population. It was likely that this positive
association between the (CAG)9 allele and CAD in the Turkish
study might be due to chance or confounding, for its sample size
was rather small (n=156) and its deviation would have little or no
effect on our null results. We agree that more studies in diverse
ethnic/racial groups are required to draw a firm conclusion.
It was noteworthy that we identified the 21-bp deletion only in
affected individuals, which was consistent with the results
from Wang et al. [11,19,38,39], but which are contradicted by
observations in other [13,14,16–18,20,32–34]. Considering that
the 21-bp deletion was firstly identified in an exceptional CAD
family displaying an autosomal-dominant pattern of inheritance
and no families in the specific context were ever available for
genetic linkage analysis thus far, the molecular case-control
association studies of unrelated samples have become the
alternative research strategy, but the results were inconsistent.
Researchers have argued strongly against this deletion as a causal
variant in the mechanisms of CAD pathopoiesis [41,42]. In view of
possibly different genetic profiles and clinical features, we cannot
jump to a conclusion regarding the cosegregation of the 21-bp
deletion with CAD until validation in well-designed, large cohort
studies. On the other hand, the susceptibility of patients with the
21-bp deletion to CAD supports the common-disease rare-variant
(minor allele frequency less than 5%) hypothesis (CDRV) rather
than the common-disease common-variant hypothesis (CDCV)
[43,44]. There exists a ‘common-variant, small-effect’ model and
also the possibility of a ‘rare-variant, large-effect’ model [34], the
question is not which model is correct, but rather what is the
relative contribution of each [43,45–48]. Although our findings
add potent evidence favoring the association of the 21-bp deletion
with CAD, the possibility of a founder effect from a common
variant, such as (CAG)n polymorphism, cannot be ruled out. The
challenge here is to decide which observed variants in MEF2A
gene could be considered as a susceptibility or causal mutation in
CAD. Our data indicate that the rare 21-bp deletion might have a
more compelling effect on CAD than the common (CAG)n
variant, and MEF2A genetic variants might, therefore, be a rare
but specific cause of CAD/MI. Needless to say, a composite effect
MEF2A Variants and Coronary Artery Disease
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determined.
Finally, some limitations of this study should be acknowledged
when interpreting the results. Firstly, it is recognized that
differences in study design, genetic heterogeneity and statistical
methods made it harder to estimate the exact underlying genetic
contribution to disease susceptibility. Moreover, some large-scale
studies [15,20,34] could not be included in our meta-analysis
because of their incomplete raw data. These could have potentially
introduced additional factors and influenced our results. Secondly,
most of the enrolled study samples, including our affected
population, were all survivors of CAD, as we could not evaluate
those who did not survive. Thirdly, considering the complex
interplay between the MEF2A gene and others that operate in the
same pathway, the single-locus based case-control study and meta-
analysis preclude the possibility of gene-gene and gene-environ-
ment interactions and may not reveal the full picture. Although
there was no evidence showing publication bias in our overall
meta-analysis, considering the above limitations, further studies
with larger sample size and different ethnic compositions, which
typically considered as small or moderate effects, are warranted to
avoid study bias.
In conclusion, our case-control study and the following meta-
analysis provide no convincing evidence for the genetic involve-
ment of MEF2A gene (CAG)n polymorphism in CAD. However,
we suggested that the 21-bp deletion might be a rare but specific
cause of CAD. As few studies are available in this field and current
evidence remains limited, this conclusion requires further
confirmation by well-designed prospective studies with adequate
methodological quality and properly controlling for possible
confounds, particularly different genetic approaches, homoge-
neous CAD patients and well-matched controls, gene-gene and
gene-environment interactions, and multiethnic groups.
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